Review Current peptide HIV type-1 fusion inhibitors
文献类型：期刊论文
| 作者 | Pang W1; Tam SC1; Zheng YT[*]1 |
| 刊名 | Antiviral Chemistry & Chemotherapy
 |
| 出版日期 | 2009 |
| 卷号 | 20期号:1页码:1-18 |
| 通讯作者 | zhengyt@mail.kiz.ac.cn |
| 合作状况 | 其它 |
| 英文摘要 | There are now 26 antiretroviral drugs and 6 fixed-dose combinations, including reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors and fusion (or entry) inhibitors, approved by the US Food and Drug Administration for clinical use. Although they are clinically effective when used in combination, none of the existing drugs are considered ideal because of toxic side effects and the ascendance of inducing drug-resistant mutants. Development of new antiviral agents is essential. In the past decades, there has been great progress in understanding the structure of HIV type-1 (HIV-1) gp41 and the mechanism of HIV-1 entry into host cells. This opened up a promising avenue for rationally designed agents to interfere with this process. A number of fusion inhibitors have been developed to block HIV-1 replication. Enfuvirtide (T20) was one of those approved for clinical use. This signalled a new era in AIDS therapeutics. It is a synthetic polypeptide with potent inhibitory activity against HIV-1 infection. However, it is sensitive to proteolytic digestion and resistant virus strains are easily induced with multiple clinical use. One of the directions in designing new fusion inhibitors is to overcome these shortages. In the past years, large numbers of promising fusion inhibitory peptides have emerged. The antiviral activities are more potent or they can act differently from that of T20. Some of these new compounds have great potential to be further developed as therapeutic agents. This article reviewed some recent developments of these peptides and the possible role in anti-HIV-1 therapy. |
| 收录类别 | 其他 |
| 资助信息 | This work was supported in part by grants from the Chinese Academy of Sciences (KSCX1-YW-R-15 and KSCX1-YW-R-24), Key Scientific and Technological projects of China (2008ZX10001-002, 2008ZX10001- 015, 2008ZX10005-005 and 2009ZX09501-029) and Yunnan province (2007BC006 and 2009CD109), 973 program (2006CB504302, 2006CB504208 and 2009CB5223006), the China Postdoctoral Science Foun- dation (20090451433) and the National Natural Sci- ence Foundation of China (U0832601 and 30671960). |
| 语种 | 英语 |
| 公开日期 | 2010-11-10 |
| 源URL | [http://159.226.149.42:8088/handle/152453/6422]  |
| 专题 | 昆明动物研究所_分子免疫药理学 昆明动物研究所_动物模型与人类重大疾病机理重点实验室 |
| 作者单位 | 1.Key Laboratory of Animal Models and Human Diseases Mechanisms, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China 2.School of Biomedical Sciences, Faculty of Medicine, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China |
| 推荐引用方式 GB/T 7714 | Pang W,Tam SC,Zheng YT[*]. Review Current peptide HIV type-1 fusion inhibitors[J]. Antiviral Chemistry & Chemotherapy,2009,20(1):1-18. |
| APA | Pang W,Tam SC,&Zheng YT[*].(2009).Review Current peptide HIV type-1 fusion inhibitors.Antiviral Chemistry & Chemotherapy,20(1),1-18. |
| MLA | Pang W,et al."Review Current peptide HIV type-1 fusion inhibitors".Antiviral Chemistry & Chemotherapy 20.1(2009):1-18. |
入库方式： OAI收割
来源：昆明动物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。